• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DNA-dependent protein kinase inhibitor as a sensitizer of radiotherapy in locally advanced rectal cancer.

作者信息

Kagawa Yoshinori, Watanabe Jun, Ando Koji

机构信息

Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan.

Department of Gastroenterological Surgery, Osaka General Medical Center, Osaka, Japan.

出版信息

J Gastrointest Oncol. 2024 Oct 31;15(5):2358-2362. doi: 10.21037/jgo-24-373. Epub 2024 Oct 9.

DOI:10.21037/jgo-24-373
PMID:39554583
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11565114/
Abstract
摘要

相似文献

1
DNA-dependent protein kinase inhibitor as a sensitizer of radiotherapy in locally advanced rectal cancer.DNA依赖性蛋白激酶抑制剂作为局部晚期直肠癌放疗的增敏剂
J Gastrointest Oncol. 2024 Oct 31;15(5):2358-2362. doi: 10.21037/jgo-24-373. Epub 2024 Oct 9.
2
Somatic NGS Analysis of DNA Damage Response (DDR) Genes , , , , and in Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemo-Radiotherapy.新辅助放化疗治疗的局部晚期直肠癌中DNA损伤反应（DDR）基因、、、和的体细胞二代测序分析
Biomedicines. 2022 Dec 13;10(12):3247. doi: 10.3390/biomedicines10123247.
3
Node-sparing modified short-course Radiotherapy Combined with CAPOX and Tislelizumab for locally Advanced MSS of Middle and low rectal Cancer (mRCAT): an open-label, single-arm, prospective, multicentre clinical trial.保留结直肠神经的改良短程放疗联合 CAPOX 和替雷利珠单抗治疗局部进展期中低位 MSS 直肠癌(mRCAT)的前瞻性、单臂、开放标签、多中心临床研究
BMC Cancer. 2024 Oct 9;24(1):1247. doi: 10.1186/s12885-024-12994-0.
4
XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy.XRCC2作为接受术前放疗的局部晚期直肠癌患者放射抗性的预测生物标志物。
Oncotarget. 2015 Oct 13;6(31):32193-204. doi: 10.18632/oncotarget.4975.
5
Targeting SGK1 enhances the efficacy of radiotherapy in locally advanced rectal cancer.靶向 SGK1 增强局部晚期直肠癌放疗疗效。
Biomed Pharmacother. 2020 May;125:109954. doi: 10.1016/j.biopha.2020.109954. Epub 2020 Feb 7.
6
Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: A study protocol of a randomized phase II/III trial (STELLAR II study).术前短程放疗联合化疗和 PD-1 抑制剂治疗局部进展期直肠癌：一项随机 II/III 期试验（STELLAR II 研究）的研究方案。
Colorectal Dis. 2024 Sep;26(9):1732-1740. doi: 10.1111/codi.17090. Epub 2024 Jul 17.
7
The efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer patients: a systematic review.新辅助放化疗联合免疫治疗局部晚期直肠癌患者的疗效和安全性：系统评价。
Front Immunol. 2024 May 15;15:1392499. doi: 10.3389/fimmu.2024.1392499. eCollection 2024.
8
Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.局部晚期直肠癌的新辅助治疗和 PD-1/PD-L1 检查点抑制剂。
Front Immunol. 2023 Mar 24;14:1149122. doi: 10.3389/fimmu.2023.1149122. eCollection 2023.
9
[Construction of a model based on multipoint full-layer puncture biopsy for predicting pathological complete response after neoadjuvant therapy for locally advanced rectal cancer].基于多点全层穿刺活检构建预测局部晚期直肠癌新辅助治疗后病理完全缓解的模型
Zhonghua Wei Chang Wai Ke Za Zhi. 2024 Apr 25;27(4):403-411. doi: 10.3760/cma.j.cn441530-20240101-00002.
10
Efficacy and safety of MR-guided adaptive simultaneous integrated boost radiotherapy to primary lesions and positive lymph nodes in the neoadjuvant treatment of locally advanced rectal cancer: a randomized controlled phase III trial.MR 引导自适应同步整合推量放疗在局部晚期直肠癌新辅助治疗中对原发灶和阳性淋巴结的疗效和安全性：一项随机对照 III 期试验。
Radiat Oncol. 2024 Sep 12;19(1):118. doi: 10.1186/s13014-024-02506-6.

本文引用的文献

1
Phase II study of long-course chemoradiotherapy followed by consolidation chemotherapy as total neoadjuvant therapy in locally advanced rectal cancer in Japan: ENSEMBLE-2.日本局部晚期直肠癌长程放化疗联合巩固化疗作为全新辅助治疗的II期研究：ENSEMBLE-2
Ann Gastroenterol Surg. 2024 Aug 3;8(6):1067-1075. doi: 10.1002/ags3.12848. eCollection 2024 Nov.
2
Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights.局部晚期直肠癌的管理：美国临床肿瘤学会指南临床见解
JCO Oncol Pract. 2025 Mar;21(3):281-286. doi: 10.1200/OP-24-00550. Epub 2024 Sep 5.
3
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.
SCRUM-MONSTAR 癌症组学生态系统：力求在精准医学领域实现飞跃。
Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206.
4
Mechanism of immune activation mediated by genomic instability and its implication in radiotherapy combined with immune checkpoint inhibitors.基因组不稳定性介导的免疫激活机制及其在放疗联合免疫检查点抑制剂中的意义。
Radiother Oncol. 2024 Oct;199:110424. doi: 10.1016/j.radonc.2024.110424. Epub 2024 Jul 10.
5
Future direction of total neoadjuvant therapy for locally advanced rectal cancer.局部进展期直肠癌新辅助治疗的未来方向。
Nat Rev Gastroenterol Hepatol. 2024 Jun;21(6):444-455. doi: 10.1038/s41575-024-00900-9. Epub 2024 Mar 14.
6
Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.在晚期实体瘤患者中开展的 peposertib 联合avelumab 或不联合姑息性放疗的 I 期研究。
ESMO Open. 2024 Feb;9(2):102217. doi: 10.1016/j.esmoop.2023.102217. Epub 2024 Feb 5.
7
A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer.一项评估 DNA-PK 抑制剂 Peposertib 联合新辅助放化疗治疗局部晚期直肠癌患者的 Ib 期研究。
Clin Cancer Res. 2024 Feb 16;30(4):695-702. doi: 10.1158/1078-0432.CCR-23-1129.
8
Short-term outcomes of a prospective multicenter phase II trial of total neoadjuvant therapy for locally advanced rectal cancer in Japan (ENSEMBLE-1).日本局部晚期直肠癌全新辅助治疗前瞻性多中心II期试验（ENSEMBLE-1）的短期结果
Ann Gastroenterol Surg. 2023 Jul 11;7(6):968-976. doi: 10.1002/ags3.12715. eCollection 2023 Nov.
9
A Phase 1 Study of the DNA-PK Inhibitor Peposertib in Combination With Radiation Therapy With or Without Cisplatin in Patients With Advanced Head and Neck Tumors.DNA-PK抑制剂培铂昔替尼联合放疗（联合或不联合顺铂）用于晚期头颈肿瘤患者的1期研究。
Int J Radiat Oncol Biol Phys. 2024 Mar 1;118(3):743-756. doi: 10.1016/j.ijrobp.2023.09.024. Epub 2023 Sep 24.
10
A new wave of innovations within the DNA damage response.DNA 损伤反应领域的新一轮创新浪潮。
Signal Transduct Target Ther. 2023 Sep 8;8(1):338. doi: 10.1038/s41392-023-01548-8.